SAN FRANCISCO – In a limited capital market where biotechs are essentially back to "begging, borrowing or stealing," the most obvious business model for staying afloat is partnering, whether with academia, government, foundations or big pharma, said Andrew Schwab, founder and managing partner at 5AM Ventures. (BioWorld Today) Read More
